Joint Rule of 40
The Rule of 40 of Joint (JYNT) as of Nov 21, 2026 is 3.59 %. In the previous year, Rule of 40 was 7.42 % — a change of -51.63% (lower).
Get this data via API
Financial Data API
Rule of 40
3.59 %
YoY
-51.63%
Last updated:
Rule of 40 of Joint is 2025 3.59 % . Rule of 40 of Joint was 2024 7.42 % . It decreases by -51.63% lower compared to the previous year.
The Joint Rule of 40 history
3 Years
10 Years
25 Years
Max
Rule of 40
Date
Rule of 40
Jan 1, 2018
26.97 USD
Jan 1, 2019
59.46 USD
Jan 1, 2020
30.48 USD
Jan 1, 2021
44.00 USD
Jan 1, 2022
27.37 USD
Jan 1, 2023
-52.93 USD
Jan 1, 2024
7.42 USD
Jan 1, 2025
3.59 USD
| YEAR | Rule of 40 | YoY |
|---|---|---|
| 3.59 % | -51.63% | |
| 7.42 % | -114.02% | |
| -52.93 % | -293.40% | |
| 27.37 % | -37.81% | |
| 44.00 % | +44.37% | |
| 30.48 % | -48.74% | |
| 59.46 % | +120.44% | |
| 26.97 % | +169.92% | |
| 9.99 % | -140.20% | |
| -24.86 % | -191.82% | |
| 27.07 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Joint Stock analysis
What does Joint do? The Joint Corp is an American company specializing in providing medical and wellness services. It was founded in 2010 and is headquartered in Scottsdale, Arizona. The company currently operates over 600 clinics in the United States and is listed on NASDAQ under the ticker symbol JYNT. Its business model focuses on treating patients with joint and muscle pain through a chain of clinics that specialize in chiropractic, physical therapy, and other wellness-based treatments. The company's main strategy for expansion is through franchise systems, providing support to franchisees in areas such as location selection, building lease, and financing. Joint clinics offer a range of products and services, including chiropractic treatments, physical therapy, sports medicine, acupuncture, supplements, and pain medication. The company has recently partnered with a franchise company in Canada to open clinics in multiple Canadian cities and plans to open clinics in other countries in the coming years. While The Joint brand is known for its affordable wellness concept, it has faced mixed reception from the chiropractic industry due to concerns about quality and patient safety. However, the company has taken steps to address these concerns by hiring qualified chiropractors and physicians and implementing strict quality controls. Overall, The Joint Corp is focused on becoming a leading wellness company in the USA and worldwide, aiming to expand and offer innovative ways to improve patient well-being. Joint is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Joint stock
Rule of 40 of Joint is 3.59 % in 2025.
On Eulerpool you can find the complete historical development of Rule of 40 Joint since 2006 – with annual values, charts, and detailed analysis.
The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Joint
All Key Metrics — Joint
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth